Zhu AX, Kang Y-K, Yen C-J, et al. REACH-2: A randomized, double-blind, placebo-controlled phase III study of ramucirumab (Cyramza) versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol 36, 2018 (suppl; abstr 4003).
Aanpassing sluiscriteria voor nieuwe dure geneesmiddelen
jan 2023 | Borstkanker, Dermato-oncologie, Gynaecologische oncologie, Immuuntherapie, Leukemie, Longoncologie, Lymfoom, Maag-darm-leveroncologie, MM, Uro-oncologie